BETOPTIC SUSPENSION SINGLE DOSE 0.25 %w/v Eye Drops Suspension

国: アイルランド

言語: 英語

ソース: HPRA (Health Products Regulatory Authority)

有効成分:

BETAXOLOL HYDROCHLORIDE

から入手可能:

Novartis Pharmaceuticals UK Ltd

ATCコード:

S01ED02

INN（国際名）:

BETAXOLOL HYDROCHLORIDE

投薬量:

0.25 %w/v

医薬品形態:

Eye Drops Suspension

処方タイプ:

Product subject to prescription which may be renewed (B)

治療領域:

Beta blocking agents

認証ステータス:

Authorised

承認日:

2017-05-05

製品の特徴

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Betoptic Suspension Single Dose 0.25% w/v, Eye Drops
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Betaxolol (as hydrochloride) 0.25% w/v.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Eye drops, suspension
A white to off white suspension.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
BETOPTIC SUSPENSION SINGLE DOSE eye drops contain a cardioselective
beta-adrenergic receptor blocker which
is indicated for the reduction of elevated intraocular pressure in
patients with ocular hypertension and chronic open-
angle glaucoma.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Shake well before each use.
ADULTS (INCLUDING THE ELDERLY)
The usual dose is one drop twice daily. Standard ocular hypotensive
agents may be used to supplement this treatment.
CHILDREN
Clinical studies to establish the safety and efficacy in children have
not been performed up to now.
When using nasolacrimal occlusion or closing the eyelids for 2
minutes, the systemic absorption is reduced.
This may
result in a decrease in systemic side effects and an increase in local
activity.
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in Section 6.1
Hypersensitivity to beta-adrenoceptor blockers.
Reactive airway disease including severe bronchial asthma or a history
of severe bronchial asthma, severe
chronic obstructive pulmonary disease.
Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or
third degree atrioventricular block not
controlled with pace-maker. Overt cardiac failure, cardiogenic shock
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___